Edgewise Therapeutics (EWTX) Stock Price, News & Analysis

Company Overview

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Key Stats

• Today's Range: $26.82 to $29.00
• 50-Day Range: $24.15 to $32.69
• 52-Week Range: $14.90 to $38.12
• Volume: 622,594 shs
• Average Volume: 960,113 shs
• Market Capitalization: $2.56 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $41.29
• Consensus Rating: Moderate Buy

Edgewise Therapeutics Stock Analysis - MarketRank™

Edgewise Therapeutics scored higher than 37% of companies evaluated by MarketBeat, and ranked 744th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Edgewise Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Edgewise Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Edgewise Therapeutics are expected to decrease in the coming year, from ($1.45) to ($1.86) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Edgewise Therapeutics is -18.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Edgewise Therapeutics is -18.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Edgewise Therapeutics has a P/B Ratio of 6.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.31% of the float of Edgewise Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Edgewise Therapeutics has a short interest ratio ("days to cover") of 8.2.

Change versus previous month

Short interest in Edgewise Therapeutics has recently increased by 4.75%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Edgewise Therapeutics does not currently pay a dividend.

Dividend Growth

Edgewise Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

11.31% of the float of Edgewise Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Edgewise Therapeutics has a short interest ratio ("days to cover") of 8.2.

Change versus previous month

Short interest in Edgewise Therapeutics has recently increased by 4.75%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.35

News Sentiment

Edgewise Therapeutics has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Edgewise Therapeutics this week, compared to 4 articles on an average week.

Search Interest

Only 1 people have searched for EWTX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Edgewise Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Edgewise Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,605,305.00 in company stock.

Percentage Held by Insiders

24.11% of the stock of Edgewise Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

EWTX Stock Analysis - Frequently Asked Questions

How have EWTX shares performed this year?

Edgewise Therapeutics' stock was trading at $26.70 at the beginning of the year. Since then, EWTX stock has increased by 4.4% and is now trading at $27.8650.
View the best growth stocks for 2025 here.

How were Edgewise Therapeutics' earnings last quarter?

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) issued its earnings results on Thursday, August, 8th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.36) by $0.02.

When did Edgewise Therapeutics IPO?

Edgewise Therapeutics (EWTX) raised $150 million in an initial public offering on Friday, March 26th 2021. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, SVB Leerink and Wedbush PacGrow served as the underwriters for the IPO.

Who are Edgewise Therapeutics' major shareholders?

Top institutional investors of Edgewise Therapeutics include Baker BROS. Advisors LP (6.50%), Novo Holdings A S (5.28%), Janus Henderson Group PLC (5.26%) and Paradigm Biocapital Advisors LP (4.75%). Insiders that own company stock include Peter A Thompson, Orbimed Advisors Llc, Holdings A/S Novo, Joanne M Donovan, Alan J Russell, Kevin Koch, Behrad Derakhshan, Jonathan C Fox, R Michael Carruthers, Marc Semigran and John R Moore.
View institutional ownership trends.

How do I buy shares of Edgewise Therapeutics?

Shares of EWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Edgewise Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Edgewise Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Tesla (TSLA), JPMorgan Chase & Co. (JPM) and First Solar (FSLR).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 2/21/2025
• Next Earnings (Estimated): 5/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EWTX
• CUSIP: N/A
• CIK: 1710072
• Web: www.edgewisetx.com
• Phone: 720-262-7002
• Fax: N/A
• Employees: 60
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $41.29
• High Stock Price Target: $51.00
• Low Stock Price Target: $30.00
• Potential Upside/Downside: +51.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.86
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-100,160,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -26.83%
• Return on Assets: -25.67%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 26.35
• Quick Ratio: 26.35

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.53 per share
• Price / Book: 6.01

Miscellaneous

• Outstanding Shares: 94,690,000
• Free Float: 71,859,000
• Market Cap: $2.58 billion
• Optionable: Optionable
• Beta: 0.20